Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.43 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31347077 | 0.82 | KDM4E (0.58) | PIM3PIM1CHEK1TTBK1TTBK2 | |
| SCHEMBL2158555 | 0.82 | KDM4E (0.58) | PIM3PIM1CHEK1TTBK1TTBK2 | |
| SCHEMBL27939078 | 0.78 | SLC22A6 (0.38) | KDM4E | |
| SCHEMBL23147921 | 0.76 | BRD4 (0.43) | — | |
| SCHEMBL29721888 | 0.76 | BRD4 (0.43) | — | |
| SCHEMBL6586825 | 0.74 | KDM4E (0.68) | KDM4EPLA2G2AL3MBTL1MEN1KMT2A | |
| SCHEMBL20692462 | 0.74 | NR4A2 (0.50) | PIM3PIM1CHEK1TTBK1TTBK2 | |
| SCHEMBL29702772 | 0.73 | NUDT1 (0.73) | TTBK1TTBK2NUDT1MAP2K1KDM4E | |
| SCHEMBL1951650 | 0.73 | NUDT1 (0.73) | TTBK1TTBK2NUDT1MAP2K1KDM4E | |
| SCHEMBL21632535 | 0.73 | JAK3 (0.46) | TTBK1TTBK2NUDT1MAP2K1CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | PIM3 863/4885PIM1 420/4885CHEK1 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.